Atrium spun out of Avidity Biosciences, which Novartis acquired in a $12 billion deal. The Atrium pipeline is led by two RNA therapies with a path to the clinic for uncommon inherited cardiological problems that haven’t any FDA-approved medicine.
The put up Atrium Therapeutics Launches With $270M for RNA Therapies Addressing Uncommon Cardio Situations appeared first on MedCity Information.
